Lawrence Klein, Ph.D.

Dr. Klein is Chief Executive Officer of Oruka Therapeutics and a member of their Board of Directors. Before joining Oruka, he was a Partner at Versant Ventures, where he invested in and helped grow early-stage biotechnology companies. He previously was a member of the CRISPR Therapeutics leadership team and helped grow the company into one of the most recognized innovative biotechnology companies in the industry. During his seven-year tenure with CRISPR, he served as Chief Business Officer before also taking on the role of Chief Operating Officer. In these roles he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs, and contribute to building the team. Prior to CRISPR, he served a variety of clients in the biopharma industry as an Associate Partner at McKinsey & Company. He currently serves as a member of the Jade Biosciences Board of Directors.

Dr. Klein holds a PhD in biophysics from Stanford University, where his research focused on T cell immunology.